-
Among veterans with risk factors for hepatitis C, a screening program yields results of limited value. The number needed to screen to yield a treatable case of hepatitis C was 451, but the number needed to screen for a successful outcome was more than 4000.
-
Middle-aged women who followed the DASH diet had a lower risk of stroke and coronary heart disease over a 24-year-period than comparable women who did not.
-
In a British study telling the patient their lung age after spirometry doubled the likelihood of their stopping smoking at one year.
-
A product containing a commonly used antimigraine drug (sumatriptan) and a NSAID (naproxen) has been approved for the treatment of acute migraine attacks.
-
Many pregnant patients ask whether it is bad to exercise regularly and vigorously, while others ask whether exercising in any way helps to improve outcome. These questions were addressed in a recent publication in the American Journal of Obstetrics & Gynecology.
-
Being pregnant puts patients in a special category where, seemingly, everything they put in their mouths, even some foods, has some risk to the fetus.
-
Cuppone and colleagues primarily from the Regina Elena National Cancer Institute in Rome, Italy, performed a meta-analysis of randomized trials comparing aromatase inhibitors with tamoxifen in early breast cancer, focusing on cardiovascular risk.
-
The authors set out to determine the preventive services and counseling provided by gynecologists, general medical physicians, or both. Using the 2000 National Health Interview Survey, the study population included women aged 18-64 years of age (with regard to Pap smear, use of tobacco, and exercise/diet counseling) and women in the 50-64 age group (previous parameters plus breast examinations, mammograms, and colon cancer screening). Sixty-two percent of patients were seen by gynecologists, 15% by general medical physicians, and 23% by both.
-
HABITS was a randomized but not placebo-controlled trial in which hormone therapy was compared to management without hormones in women with menopausal symptoms who had been previously treated for Stage I or Stage II breast cancer.1 Concomitant tamoxifen treatment was allowed in the HABITS patients but not aromatase inhibiters.
-
The SWAN is a multisite, multi ethnic, prospective, observational, longitudinal study of 3302 women who were enrolled between 1995-1997.